Figures




FIG. 1



BRD3
BRD4
BRD2
log2ratio_ABBV-744 vs DMSO
-log10 (adj. p-value)
BRD3
BRD4
BRD2
log2ratio_C1PI vs DMSO
-log10 (adj. p-value)

FIG. 2A



Brd2
Brd3
Brd4
log2ratio_ABBV-744 vs DMSO
-log10 (adj. p-value)
Brd3
Brd2
Brd4
log2ratio_C1PI vs DMSO
-log10 (adj. p-value)

FIG. 2B



60000
40000
20000
0
GFP (MFI)
Untransfected
Non targeting siRNA
Target specific siRNA
Wild type RBL

FIG. 3A



20
15
10
0.5
R2 = 0.84
Cor1 MFI, x10⁴
500 1000 1500 2000 2500
BRD3 MFI

FIG. 3B



PASI Score (Day 7)
****
0
1
2
3
4
UT
Veh PO
C1PI 10 MPK PO
C1PI 30 MPK PO
Deucra 10 MPK PO
GSK620 10 MPK PO
Ear thickness on Day 7 [mm]
****
0.0
0.2
0.4
0.6
UT
Veh PO
C1PI 10 MPK PO
C1PI 30 MPK PO
Deucra 10 MPK PO
GSK620 10 MPK PO

FIG. 4A



Cor 1 - Fold change
IL-17A - Fold change
TNFa - Fold change
UT
Veh PO
C1PI 10 MPK PO
C1PI 30 MPK PO
Deucra 10 MPK PO
GSK620 10 MPK PO
*
***
****
***
****
***
****
***
****

FIG. 4B



DMSO
C1PI
CSA
Tofacitinib
OTII T cell responses
[H]3- Thymidine incorporation (CPM)
150
100
50
0
Infectious antigen
Auto (self) antigen
Infectious antigen
Auto (self) antigen
Infectious antigen
Auto (self) antigen
Infectious antigen
Auto (self) antigen

FIG. 5